[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351290-105":59,"doc-detail-351290-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","post-translational-protein-lactylation-modification-in-lung-cancer-an-emerging-targeted-therapeutic-strategy","Post-translational protein lactylation modification in lung cancer - an emerging targeted therapeutic strategy","","Lung cancer remains highly prevalent and lethal, largely due to late diagnosis, immune evasion, and metastatic dissemination that drive survival declines. Targeted therapies and immunotherapies have improved management, yet therapeutic resistance and limited response durability persist. This review examines lactylation as a newly recognized post-translational modification and potential therapeutic vulnerability. It outlines lactylation-linked molecular mechanisms, highlighting enzymatic regulation, tumor metabolic reprogramming, immune escape, and resistance-associated signaling, and evaluates translational potential as biomarkers and actionable targets, while noting current clinical limits and unmet standardization needs.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/post-translational-protein-lactylation-modification-in-lung-cancer-an-emerging-targeted-therapeutic-strategy/351290/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/post-translational-protein-lactylation-modification-in-lung-cancer-an-emerging-targeted-therapeutic-strategy/351290.png","ImageObject",300,407,{"name":92,"@type":93},"Jake","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"Why is lung cancer difficult to treat despite targeted therapies and immunotherapies?","Question",{"text":112,"@type":113},"Because many patients develop immune evasion and metastatic dissemination, and because therapeutic resistance and limited durability of response remain major challenges.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is lactylation in the context of this review?",{"text":117,"@type":113},"Lactylation is described as a post-translational modification where lactate groups covalently bind to protein lysine residues, enabling heritable changes in gene expression without DNA sequence alterations.",{"name":119,"@type":110,"acceptedAnswer":120},"How does lactylation relate to tumor progression and treatment resistance?",{"text":121,"@type":113},"The review explains that lactylation reshapes tumor metabolism, contributes to immune evasion, and modulates resistance-associated signaling pathways through effects on histone and non-histone proteins.",{"name":123,"@type":110,"acceptedAnswer":124},"What barriers limit clinical translation of lactylation-targeted strategies?",{"text":125,"@type":113},"Clinical translation is constrained by the lack of specific intervention tools, standardized detection methodologies, and robust human data; future work should emphasize precise targeted approaches and large-scale longitudinal validation.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},351290,1790182417,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},962084928904,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","TYPE Review  \nPUBLISHED 11 March 2026  \nDOI 10.3389/fimmu.2026.1734414  \nOPEN ACCESS  \nEDITED BY  \nNaoe Taira Nihira,  \nSt. Marianna University Graduate School of Medicine, Japan  \nREVIEWED BY  \nWeifeng Hong,  \nFudan University, China Glenn E. Simmons Jr.,  \nCornell University, United States  \n*CORRESPONDENCE  \nChangying Guo  \n [guochangying@ncmc.edu.cn](guochangying@ncmc.edu.cn)  \nRECEIVED 28 October 2025  \nREVISED 21 February 2026  \nACCEPTED 24 February 2026  \nPUBLISHED 11 March 2026  \nCITATION  \nLi Y, Li Z, Liu X, Qiu Z, Zhang R, Li H, Gao C and Guo C (2026) Posttranslational protein lactylation modiﬁcation in lung cancer: an emerging targeted therapeutic strategy. Front. Immunol. 17:1734414 .  \ndoi: 10.3389/fimmu.2026.1734414  \nCOPYRIGHT  \n© 2026 Li, Li, Liu, Qiu, Zhang, Li, Gao and Guo. This is an open-access article distributed under the terms of the  \nCreative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nPost-translational protein lactylation modiﬁcation in lung cancer: an emerging targeted therapeutic strategy  \nYongxuan Li 1,2, Zhao Li 2, Xingfei Liu 3, Zhengzhou Qiu 4,5, Ruilin Zhang 1,2, Huan Li 1,2, Chenggen Gao 1,2 and Changying Guo 2*  \n1Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China, 2 Department of Thoracic Surgery, Jiangxi Cancer Hospital, The Second Afﬁliated Hospital of Nanchang Medical College, Jiangxi Cancer Institute, Nanchang, Jiangxi, China, 3 Department of Cardiothoracic Surgery, Suzhou BOE Hospital, Suzhou, Jiangsu, China, 4 Department of Oncology, The Forth Afﬁliated Hospital of Soochow University, Suzhou, Jiangsu, China, 5Suzhou Medical College, Soochow University, Suzhou,  \nJiangsu, China  \nLung cancer remains the second most prevalent malignancy worldwide and is characterized by persistently high incidence and mortality rates. As the disease progresses, most patients develop immune evasion and metastatic dissemination, which represent major threats to overall survival. The advent of targeted therapies and immunotherapies has fundamentally reshaped the clinical management of lung cancer; however, therapeutic resistance and limited durability of response remain critical challenges. Lactylation has recently emerged not only as a novel post-translational modiﬁcation but also as a potential therapeutic vulnerability in lung cancer. By modulating the activity, stability, and transcriptional functions of both histone and non-histone proteins, lactylation reshapes tumor metabolism, immune evasion, and resistance-associated signaling pathways. Importantly, growing evidence suggests that therapeutic strategies targeting lactylationrelated pathways may offer new opportunities to improve outcomes in patients with advanced lung cancer and overcome acquired resistance to existing therapies. In this review, we systematically delineate the molecular mechanisms underlying lactylation, with particular emphasis on the enzymatic machinery governing lactylation dynamics and its regulatory network. We synthesize current evidence describing how lactylation-driven signaling programs contribute to lung cancer progression, immune escape, and treatment resistance, highlighting the complex interplay between lactylation pathways and lung cancer pathobiology. Furthermore, we critically evaluate the translational potential of lactylation sites and their downstream effectors as diagnostic and prognostic biomarkers, as well as actionable therapeutic targets. Collectively, these ﬁndings support the concept that targeting lactylation-associated regulatory circuits represents an emerging and potentially more selective therapeutic strategy for lung cancer. Nevertheless, clinical trans","cbCaieU9a9NzLrU9","https://ap.wps.com/l/cbCaieU9a9NzLrU9","pdf",5669386,18,"English","# Introduction\n## Lactylation and epigenetic regulation in lung cancer\n## Lactylation as a therapeutic vulnerability\n# Mechanistic overview\n## Enzymatic machinery and regulatory networks\n## Lactylation-driven signaling in progression, immune escape, and resistance\n# Translational evaluation\n## Diagnostic and prognostic biomarker potential\n## Therapeutic target potential\n# Challenges and future directions\n## Clinical translation constraints\n## Needed tools, detection methodologies, and human validation","[{\"question\":\"Why is lung cancer difficult to treat despite targeted therapies and immunotherapies?\",\"answer\":\"Because many patients develop immune evasion and metastatic dissemination, and because therapeutic resistance and limited durability of response remain major challenges.\"},{\"question\":\"What is lactylation in the context of this review?\",\"answer\":\"Lactylation is described as a post-translational modification where lactate groups covalently bind to protein lysine residues, enabling heritable changes in gene expression without DNA sequence alterations.\"},{\"question\":\"How does lactylation relate to tumor progression and treatment resistance?\",\"answer\":\"The review explains that lactylation reshapes tumor metabolism, contributes to immune evasion, and modulates resistance-associated signaling pathways through effects on histone and non-histone proteins.\"},{\"question\":\"What barriers limit clinical translation of lactylation-targeted strategies?\",\"answer\":\"Clinical translation is constrained by the lack of specific intervention tools, standardized detection methodologies, and robust human data; future work should emphasize precise targeted approaches and large-scale longitudinal validation.\"}]","Post-translational protein lactylation modification in lung cancer - an emerging targeted therapeutic strategy | PDF",1790093406,45,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e6ae23270b5d93d831d798c64454a706.webp",983,1389,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c83d0376cbc1a1ffe218680115e32082.webp",982,1388,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3884e545cedd597abf583d904a60a9bb.webp",981,1386,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8fed0c4180ac5b16d12f36f2665456f3.webp",980,1385]